Eye anomalies and neurological manifestations in patients with PAX6 mutations

Yin-Hsuan Chien,1 Hsiang-Po Huang,2 Wuh-Liang Hwu,3,4 Yin-Hsiu Chien,3,4 Tseng-Ching Chang,1 Ni-Chung Lee1,4

1Department of Pediatrics, Taipei City Hospital, ZhongXing Branch, Taipei, Taiwan; 2Department of Medical Research, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; 3Department of Medical Genetics, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; 4Department of Pediatrics, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

Purpose: Mutations in the paired box 6 (PAX6) gene cause a wide variety of eye anomalies, including aniridia. PAX6 mutations are not well described in the Chinese population so this study is aimed at exploring the role of PAX6 mutations in Taiwanese patients with congenital eye anomalies.

Methods: Seventeen patients with single or multiple congenital eye anomalies were enrolled. Genomic DNA was prepared from venous blood leukocytes, and the coding regions of PAX6 were analyzed by PCR and direct sequencing. Clinical manifestations of the patients were then correlated to PAX6 mutations.

Results: Five PAX6 mutations were identified in one case each. Three mutations c.317T>A (p.L106X), c.142–1G>T, and c.656del10 (p.Q219QfsX20) were novel and the other two, c.331delG (p.V111SfsX13) and c.949C>T (p.R317X), have been reported. All five cases had aniridia; three had other eye anomalies; and four had developmental delay. Only one case had other affected family members. In the ten cases that had no PAX6 mutation, only one had aniridia.

Conclusions: Both novel and known PAX6 mutations were identified in the current study, and PAX6 mutations were closely associated with aniridia. Absence of a positive family history does not exclude PAX6 mutation. The frequent occurrence of developmental delay in patients with PAX6 mutation argues for a prompt diagnosis of the disease.

Aniridia is a rare ocular anomaly characterized by defects of iris tissue, ranging from mild iris hypoplasia to almost total absence of iris [1]. It occurs with an incidence of 1:64,000 to 1:100,000 [2,3]. Two-thirds of the cases show autosomal dominant inheritance with complete penetrance, while others are sporadic [3–5]. Clinical manifestations of patients varied from isolated iris involvement to panocular anomalies involving the cornea (opacity), anterior chamber angle (glaucoma), lens (dislocation and/or cataracts), retina (foveal dysplasia), and macular and optic nerve (hypoplasia) [2]. Aniridia can be associated with Wilms tumor; aniridia, genitourinary disorders, and mental retardation (WAGR syndrome); Gillespie syndrome (aniridia, cerebellar ataxia, and mental deficiency); absent patella; unilateral renal agenesis and mild psychomotor retardation; congenital adrenal hypoplasia and dysmorphism; sensorineural deafness; Marfan syndrome; Smith–Opitz syndrome; Biemond syndrome; XXXXY chromosomal anomalies; or Badet–Biedl syndrome [2,6–13].

Several genes, including the paired box 6 (PAX6), paired-like homeodomain 3 (PITX3), cone-rod homeobox (CRX), guanylate cyclase 2D, membrane (retina-specific; GUCY2D/RETGCI), peripherin 2 (PRPH/RDS), retinal pigment epithelium-specific protein 65kDa (RPE65), paired box 2 (PAX2), paired box 3 (PAX3), microphthalmia-associated transcription factor (MITF), jagged 1 (JAG1), and retina and anterior neural fold homeobox (Rx), and FOXC1, are important for eye embryogenesis [1,14,15]. Among them, PAX6, PITX2, FOXC1, and FLHL7 are associated with iris defects. Haploinsufficiency or dominant negative mutation of PAX6 leads to aniridia, congenital cataract, Peter’s anomaly, Gillespie syndrome, and midline fusion defects, while complete deficiency of PAX6 leads to anophthalmia [1,3,4]. Mutations of PITX2 result in Rieger’s syndrome (anterior segment abnormalities, glaucoma, tooth anomalies, umbilical stump abnormalities); mutations of FOXC1 result in Rieger’s syndrome (type 3); mutations of FLHL7 cause anterior segment anomaly with glaucoma (abnormal iridocorneal angle differentiation, iris stromal hypoplasia, and elevated intraocular pressure/glaucoma) [1,14–17].

PAX6 is a transcriptional regulator in the early development of the ocular system, central nervous system, and gastrointestinal system [5,18]. This gene contains 14 exons and encodes a 422-amino acid polypeptide containing two DNA-binding domains, a bipartite paired domain, and a paired type homeodomain [4]. The paired domain, which is...
coded by exons 5–7 of PAX6, has two subdomains: the relatively conserved 74-amino acid NH2-terminal subdomain and the more divergent 54-amino acid COOH-terminal subdomain. The latter subdomain is a common place for mutations [4,19]. Currently there are around 500 mutations that have been reported (Human PAX6 Allelic Variant Database [HPAVD]) [20]. Most PAX6 nonsense mutations lead to aniridia, while missense mutations are related to foveal hypoplasia, congenital cataracts, or anterior segment anomalies [21,22].

There has been no systemic study for PAX6 mutations in the Chinese population [23–25]. In this study, we analyzed the coding sequences of PAX6 in 17 patients with eye anomalies. Three novel and two known heterozygous mutations were detected. Only one patient had other affected family members, but intrafamilial variation was prominent.

METHODS

From 2003 to 2009, 17 patients (nine males and eight females) with single or multiple congenital eye anomalies diagnosed in two hospitals were enrolled in the study after informed consent. They were healthy except for their eye and neurological deficits. The study protocol included slit lamps and neurological examinations, brain Magnetic Resonance Imaging (MRI), pedigree analysis, and PAX6 gene analysis.

Genomic DNA was isolated from 5 milliliters of venous blood using a QIAamp DNA blood mini kit (Qiagen®, Hilden, Germany). PAX6 coding regions and their flanking intronic sequences were amplified by PCR (Table 1). The PCR products were purified by Gel-M™ Gel Extraction System (Viogene®, Taipei, Taiwan) and analyzed by direct sequencing using the ABI Prism Big Dye dideoxy chain terminator cycle sequencing kit and the ABI Prism 310 genetic analyzer (Applied Biosystem, Foster City, CA). PAX6 cDNA was numbered starting from the translation initiation site (NM_000280.3). Mutations were confirmed by sequencing from the opposite strand and by co-segregation of the lesion and disease within the family. Phenotypes of the patients were retrieved from the medical charts. Clinical manifestations of patients were then correlated to PAX6 mutations.

RESULTS

Of the 17 indexed patients, five had PAX6 mutations. All five patients had aniridia, and two of them had fovea hypoplasia (Table 2). The five heterozygous mutations are c.142–1G>T, c.317T>A (p.L106X), c.331delG (p.V111SfsX13), c.656del10 (p.Q219QfsX20), and c.949C>T (p.R317X) (Table 2). Mutation c.949C>T and c.331delG have been reported previously [26]. C.949C>T is widespread in different countries, while c.331delG is found only in the USA. Mutation c.317T>A, c.142–1G>T, and c.656del10 have not been previously reported. Both c.317T>A and c.656del10 produce prematurely stopped polypeptides. Mutation c.142–1G>T is located at the splicing consensus sequence of intron 5b and is likely to produce splicing errors similar to reported mutations c.141+1 G>A, c.141+2T>C, and c.142–2A>G [20, 27].

Among the five patients, only patient 2 had other affected family members. He and his mother accepted PAX6 gene analysis and both of them had the c.949C>T mutation (Figure 1. V-2, IV-2). There were eight individuals in this four-generation family who had congenital eye anomalies (Figure 1). Their anomalies included bilateral aniridia, cataract, glaucoma, and jerk horizontal nystagmus (Figure 1). They all had intact retina, choroids, and optic nerve. All other patients, except patient 2, were sporadic. Interestingly, four cases (patient 2 to 5) had delays in gross motor, fine motor, language, and cognition to a variable extent. Patient 2 could not sit until 10 months of age and started babbling only after 1 year of age. After the correction of a congenital hip dislocation and aggressive physical therapy, he walked at 19 months of age and climbed stairs with assistance at the age of 2 years. Pincer grasp was not observed until 12 months of age. Patient 3 walked with support at the age of 13 months and said

### Table 1. Primers used to amplify the PAX6 gene.

| Exon | Amplified length (bp) | Forward primer (5' to 3') | Reverse primer (5' to 3') |
|------|-----------------------|---------------------------|--------------------------|
| 1    | 645                   | GCATGTGCGCGAGTTAG         | CCTCTCGGTGAAACTTCTC      |
| 2    | 645                   | GCATGTGCGCGAGTTAG         | CCTCTCGGTGAAACTTCTC      |
| 3    | 676                   | AGAGAGCCATGGACGTAG        | GTGCCGAGTTCCCTGTGC       |
| 4    | 676                   | AGAGAGCCATGGACGTAG        | GTGCCGAGTTCCCTGTGC       |
| 5    | 373                   | TGAGGATCATGTTGGTGGT       | GAAATGAGAGGCGGGTGGT      |
| 6    | 388                   | CGTAAAGCTTCATGGATTAATGC  | AGAGAGGGAAGGGAGGAGGTA    |
| 7    | 333                   | GGTGTTGGGTAGCCGTGAGAT    | AAACCGCTAGAGGAATAGGT     |
| 8    | 355                   | GGCCTCGGAGATATATGGCT     | CAAAAGGCGAGCTGAAAT      |
| 9    | 385                   | AGTGAGACCGAGATGGTAGT     | TGGGACAGGTAGGCACGTG     |
| 10   | 537                   | AGCCAGGTTGATGCGAGG        | TCAAGGGGTCAGACACAG       |
| 11   | 537                   | AGAGTGGGATGAGGAGCAGAAAG  | TCAAGGGGTCAGACACAG       |
| 12   | 345                   | CAGACTTGTCCGGAGCAAGTCCC  | TAAACACGCCCCTCAAAAG     |
| 13   | 373                   | TTTCTGAGGGTGTCATTTTTATGG | CGGCTCTAACAGCCATTATTT    |
| No | Inheritance | Nucleotide change* | Predicted protein change* | Location | Previously reported | Eye anomalies | Extraocular manifestations |
|----|-------------|--------------------|--------------------------|----------|---------------------|--------------|--------------------------|
| 1  | sporadic    | c.317T>A           | p.L106X                  | Exon 6   | no                  | aniridia, foveal hypoplasia, pendular nystagmus | congenital hip dislocation, developmental delay |
| 2  | Familial    | c.949C>T           | p.R317X                  | Exon 11  | PAX6 database**     | aniridia, cataract, nystagmus              | developmental delay |
| 3  | sporadic    | c.331delG          | p.V111SfsX13             | Exon 6   | PAX6 database**     | aniridia                        | developmental delay |
| 4  | sporadic    | c.142–1G>T         | Abnormal splicing        | Exon 5b  | no                  | aniridia, nystagmus               | mild developmental delay |
| 5  | sporadic    | c.656del10         | p.Q219QfsX20             | Exon 8   | no                  | aniridia, horizontal pendular nystagmus, foveal hypoplasia | developmental delay |

The asterisk indicates that only one mutation is present in each patient with an autosomal dominant disease. The double asterisk refers to the Human PAX6 Allelic Variant Database (HPAVD).
“papa” and “mama” at 21 months. His brain echo was normal. Patient 4 was noted to have a small subependymal cyst at birth and head lag at age 4 months, but he did not return for follow up thereafter. Patient 5 could not sit up or turn over at the age of 7 months.

Phenotypes of the 12 PAX6 mutation-negative cases are summarized in Table 3. Only one of the 12 cases without PAX6 mutation had aniridia. Five of them had microphthalmos, three had dysmorphic facial features, and two had developmental delay.

**DISCUSSION**

In this study we identified five PAX6 mutations in 17 patients with congenital eye anomalies, resulting in a mutation detection rate of approximately 30% (5/17) in all patients with congenital eye anomalies or 83% (5/6) in patients with aniridia. Our detection rate is comparable with previous reports that 30%–80% of patients with aniridia have PAX6 mutations [28–30].

There were eight reports, four in English and four in Chinese, each mentioned a PAX6 mutation in one Chinese family with aniridia. The reported mutations, including c.1286delC (c.924delC), c.483del9 (c.121_129del9), IVS10+1G>A, c.1080C>T (c.718C>T), and c.857delG (c.495delG) [23,24,31–36], surprisingly none occurred in our population. That each mutation occurs independently demonstrates the great diversity of PAX6 mutations in the Chinese population. The large proportion of sporadic cases in the current study also suggests the diversity of PAX6 mutations.

In our cohort, 80% (4/5) of patients with the PAX6 mutation had developmental delay. This high incidence of developmental delay is unexpected. Patients with aniridia and neurologic problems were more linked to WAGR syndrome (75% have mental retardation), Gillespie’s syndrome, chromosome anomalies, or PAX6 gene duplication [2,4,37–39]. Although we did not exclude large fragment gene deletions in the current study, none of our patients had syndromic aniridia. Deletions not detectable by DNA sequencing and associated with isolated aniridia have been reported, but they are present only in a small fraction of patients [40,41].

Several PAX6 mutations have been associated with mild mental retardation (c.-129+2T>A, c.111_141ins, R44X, S74G, I87R, S119R, Q135X, W257X, C719A, c.1267dupT, and 1.3 Mb deletion from 3′ UTR of PAX6 gene at 11p14.1-p13) [20,29,42–46]. One patient with c.-129+2T>A mutation

---

**Table 3. Phenotypes of patients who have eye anomalies but no PAX6 mutation.**

| Associated organ | Phenotypes | Number of cases* |
|------------------|------------|-----------------|
| Eye | Microphthalmos | 5 |
| | Microcornea | 2 |
| | Eyelid coloboma | 2 |
| | non-specified eye anomaly | 2 |
| | Aniridia | 1 |
| | Cornea whitish plaque, Congenital cataract, Choridal coloboma, Anophthalmos, Strabismus | One each |
| Central nervous system | Developmental delay | 2 |
| | Ventriculomegaly | 2 |
| | Periventricular cyst, Hemiparesis, Seizure, Corpus callosum hypoplasia | One each |
| Genitourinary | Small kidney | 2 |
| | Vesiculoureteral reflux, Cryptorchidism | One each |
| Cardiac | Coarctation of aorta, Patent ductus arteriosus | One each |
| Skeletal | Congenital hip dislocation | 1 |
| Others | Dysmorphism | 3 |
| | Choanal atresia, Transient congenital hypothyroidism | One each |

The total number of patients = 12
had hand tremors and learning disabilities [6]; a boy with c.111_141ins had intellectual impairment [29]; microcephaly, developmental delay, and several minor dysmorphic features were noted in the sporadic patient with I87R mutation [20]; one large family with S74G mutation showed neurodevelopmental defects with or without other associated brain anomalies [46]. Occasionally, mental retardation occurred in only a portion of the affected family members [20,42]. In the Human PAX6 Allelic Variant Database, one of the three cases with S119R mutation had a learning disability and behavioral change; one of the 20 cases with c.1267dupT mutation was recorded to have developmental delay and autistic behavior. The mutations discovered in our series (c.142–1G>T, c.317T>A, c.940C>T, c.331delG, and c.656del110) are different from these reported cases with mental retardation. However the mild developmental delay in this study could have been neglected by other studies because of the vision problems of patients. The global delay in case 2 could not be explained by his vision problem or hip dislocation. Other cases in the current study also involved only gross motor or speech problems, which were difficult to explain by poor visual activity.

PAX6 gene expression is seen after the end of gastrulation in the anterior neural plate [15]. In a mouse model, Pax6 is widely expressed in the developing eye (optic cup, lens, and overlying surface ectoderm) and in specific regions of the developing brain (frontal cortex, epithalamus, ventral tagmental area, pons, external granular layer of cerebellum, fovea isthmi, olfactory bulb, septum, olfactory neuroepithelium) [47,48]. PAX6 has been suggested as being expressed in conjunction with other PAX family members in the early regionalization of the brain [47,48]. Recently, the interactions of Pax6 with developing neocortex transcription factors T-box brain gene 1 (Tbr1), eomesoderm homolog (Tbr2), neurogenin 2 (Ngne2) and achaete-scute complex homologue 1 (Mash-1) further demonstrate the role of PAX6 in the developing neocortex [49–51]. The PAX6 heterozygous mouse has absent olfactory bulb, decreased cortical neurons and cortical plate thickness, and altered dorsoventral patterning of the forebrain [45]. In patients with PAX6 mutation, polymicrogyria, absence of pineal gland, and lack of the anterior commissure have all been reported [52,53]. Therefore, it is possible that patients with PAX6 mutation have neurologic manifestations.

In conclusion, we demonstrated the mutation spectrum and neurologic manifestations of patients with PAX6 mutation in Chinese. Most patients with aniridia had PAX6 mutations. Other associated problems, such as developmental delay and even congenital hip dislocations, may also be important. Therefore, detailed neurologic examination and close observation of development is important for patients with aniridia. Early institution of physical therapies for patients with developmental delay should be able to improve their long-term prognosis.

ACKNOWLEDGMENTS
This project was partially supported by grants from National Taiwan University Hospital (NTUH.94A08–2 and NTUH. 95A13–2). The authors thank Ms Yi-Li Liu and I-Ching Huang from department of Medical Research of National Taiwan University Hospital for their assistance with DNA sequencing.

REFERENCES
1. Guercio JR, Martyn LJ. Congenital malformations of the eye and orbit. Otolaryngol Clin North Am 2007; 40:113-40. [PMID: 17346564]
2. Nelson LB, Spaeth GL, Nowinski TS, Margo CE, Jackson L. Aniridia. A review. Surv Ophthalmol 1984; 28:621-42. [PMID: 6330922]
3. Brauner SC, Walton DS, Chen TC. Aniridia. Int Ophthalmol Clin 2008; 48:79-85. [PMID: 18427263]
4. Lee H, Khan R, O’Keefe M. Aniridia: current pathology and management. Acta Ophthalmol 2008; 86:708-15. [PMID: 18937825]
5. Ton CC, Hirvonen H, Miwa H, Weil MM, Monaghan P, Jordan T, van Heyningen V, Hastie ND, Meijers-Heijboer H, Drehslcr M, Royer-Pokora B, Collins F, Swaroop A, Strong LC, Saunders GF. Positional cloning and characterization of a paired box- and homeobox-containing gene from the aniridia region. Cell 1991; 67:1059-74. [PMID: 1684738]
6. Ticho BH, Hilchle-Schmidt C, Egel RT, Braboulis EI, Howarth RJ, Robinson D. Ocular findings in Gillespie-like syndrome: association with a new PAX6 mutation. Ophthalmic Genet 2006; 27:145-9. [PMID: 17148041]
7. Mirkinson AE, Mirkinson NK. A familial syndrome of aniridia and absence of the patella. Birth Defects Orig Artic Ser 1975; 11:129-31. [PMID: 1218204]
8. Sommer A, Rathbun MA, Battles ML. Letter: A syndrome of partial aniridia, unilateral renal agenesis, and mild psychomotor retardation in siblings. J Pediatr 1974; 85:870-2. [PMID: 4419812]
9. Sachdev MS, Sood NN, Kumar H, Ghose S. Bilateral aniridia with Marfan's syndrome and dental anomalies—a new association. Jpn J Ophthalmol 1986; 30:360-6. [PMID: 3586403]
10. Zamzam AM, Sheriff SM, Phillips CI. Aniridia, ectopia lentis, abnormal upper incisors and mental retardation—an autosomal recessive syndrome. Jpn J Ophthalmol 1988; 32:375-8. [PMID: 3266265]
11. Coman DJ, White SM, Amor DJ. Two siblings with 46,XY DSD, congenital adrenal hyperplasia, aniridia, craniofacial, and skeletal abnormalities and intrauterine growth retardation: a new syndrome? Am J Med Genet A 2007; 143A:2085-8. [PMID: 17702017]
12. Courteney-Harris RG, Mills RP. Aniridia and deafness: an inherited disorder. J Laryngol Otol 1990; 104:419-20. [PMID: 2370470]
13. Verloes A, Temple IK, Bonnet S, Bottani A. Coloboma, mental retardation, hypogonadism, and obesity: critical review of the so-called Biemond syndrome type 2, updated nosology, and delineation of three “new” syndromes. Am J Med Genet 1997; 69:370-9. [PMID: 9098485]
van Heyningen V. Developmental eye disease—a genome era paradigm. Clin Genet 1998; 54:272-82. [PMID: 9831337]

Barishak RY, Ofri R. Embryogenetics: gene control of the embryogenesis of the eye. Vet Ophthalmol 2007; 10:133-6. [PMID: 17450702]

Perveen R, Lloyd IC, Clayton-Smith J, Churchill A, van Heyningen V, Hanso I, Taylor D, McKeown C, Super M, Kerr B, Winter R, Black GC. Phenotypic variability and asymmetry of Rieger syndrome associated with PITX2 mutations. Invest Ophthalmol Vis Sci 2000; 41:2456-60. [PMID: 10937553]

Ito YA, Footz TK, Berry FB, Mirzayans F, Yu M, Khan AO, Walter MA. Severe molecular defects of a novel FOXC1 W152G mutation result in aniridia. Invest Ophthalmol Vis Sci 2009; 50:3573-9. [PMID: 19279310]

Traboulsi EI, Ellison J, Sears J, Maumenee IH, Avallone J, Mooney BG. Aniridia with preserved visual function: a report of four cases with no mutations in PAX6. Am J Ophthalmol 2008; 145:760-4. [PMID: 18243151]

Epstein J, Cai J, Glaser T, Jepeal L, Maas R. Identification of a PAX6 mutation associated with hypoplastic left heart syndrome due to aniridia. Mol Vis 2006; 12:644-8. [PMID: 16785583]

Baum L, Pang CP, Fan DS, Poon PM, Leung YF, Crolla JA, Benzacken B, Verloes A. Three molecular mechanisms for aniridia cases. Mol Vis 2007; 13:1245-50. [PMID: 17679940]

Kang Y, Yuan HP, Li YY. A novel mutation of the PAX6 gene in a Chinese family with aniridia. Mol Vis 2008; 14:1650-8. [PMID: 17679951]

Cong RC, Song SJ, Liu YZ. Study of genetic mutation locus in a family with congenital aniridia. Yi Chuan 2008; 30:1301-6. [PMID: 18930890]

Brémond-Gignac D, Crolla JA, Copin H, Guichet A, Bonneau D, Taine L, Lacombe D, Baumann C, Benacken B, Verloes A. Combination of WAGR and Potocki-Snadder contiguous deletion syndromes in a patient with an 1p11.2-p14 deletion. Eur J Hum Genet 2005; 13:409-13. [PMID: 15702131]

Brémond-Gignac D, Gérard-Blanluet M, Copin H, Piton P, Baumann C, Crolla JA, Benacken B, Verloes A. Three patients with hallucal polydactyly and WAGR syndrome, including discordant expression of Wilms tumor in MZ twins. Am J Med Genet A 2005; 134:422-5. [PMID: 15779023]

D’Elia AV, Pellizzari L, Fabbro D, Pianta A, Divizia MT, Rinaldi R, Grammatico B, Grammatico P, Ardino C, Damante G. A deletion 3’ to the PAX6 gene in familial aniridia cases. Mol Vis 2007; 13:1245-50. [PMID: 17679951]

Redeker EJ, de Visser AS, Bergen AA, Mannens MM. Multiplex ligation-dependent probe amplification (MLPA) enhances the molecular diagnosis of aniridia and related disorders. Mol Vis 2008; 14:836-40. [PMID: 18483559]

Malandrini A, Mari F, Palmieri S, Gambelli S, Berti G, Bruttini M, Bardelli AM, Williamson K, van Heyningen V, Renieri A. PAX6 mutation in a family with aniridia, congenital ptosis, and mental retardation. Clin Genet 2001; 60:151-4. [PMID: 11553050]

Graziano C, D’Elia AV, Mazzanti L, Moscano F, Guidelli Guidi S, Scarano E, Turchetti D, Franzoni E, Romeo G, Damante G, Seri M. A de novo nonsense mutation of PAX6 gene in a patient with aniridia, ataxia, and mental retardation. Am J Med Genet A 2007; 143A:1802-5. [PMID: 17595013]

Gronskov K, Olsen JH, Sand A, Pedersen W, Carlsen N, Bak Jylling AM, Lyngbye T, Brøndum-Nielsen K, Rosenberg T. Population-based risk estimates of Wilms tumor in sporadic aniridia. A comprehensive mutation screening procedure of PAX6 identifies 80% of mutations in aniridia. Hum Genet 2001; 109:11-8. [PMID: 11479730]

Sun DG, Yang JH, Tong Y, Zhao GJ, Ma X. A novel PAX6 mutation (c.1286delC) in the patients with hereditary congenital aniridia. Yi Chuan 2008; 30:1301-6. [PMID: 18930890]

© 2009 Molecular Vision
44. Ticho BH, Hilchie-Schmidt C, Egel RT, Traboulsi EI, Howarth RJ, Robinson D. Ocular findings in Gillespie-like syndrome: association with a new PAX6 mutation. Ophthalmic Genet 2006; 27:145-9. [PMID: 17148041]

45. Davis LK, Meyer KJ, Rudd DS, Librant AL, Epping EA, Sheffield VC, Wassink TH. Pax6 3′ deletion results in aniridia, autism and mental retardation. Hum Genet 2008; 123:371-8. [PMID: 18322702]

46. Dansault A, David G, Schwartz C, Jaliffa C, Vieira V, de la Houssaye G, Bigot K, Catin F, Tattu L, Chapin C, Halimi P, Roche O, Van Regemorter N, Munier F, Schorderet D, Dufier JL, Marsac C, Riequier D, Menasche M, Penfornis A, Abitbol M. Three new PAX6 mutations including one causing an unusual ophthalmic phenotype associated with neurodevelopmental abnormalities. Mol Vis 2007; 13:511-23. [PMID: 17417613]

47. Hanson I, Van Heyningen V. Pax6: more than meets the eye. Trends Genet 1995; 11:268-72. [PMID: 7482776]

48. Stoykova A, Gruss P. Roles of Pax-genes in developing and adult brain as suggested by expression patterns. J Neurosci 1994; 14:1395-412. [PMID: 8126546]

49. Englund C, Fink A, Lau C, Pham D, Daza RA, Bullone A, Kowalczyk T, Hevner RF. Pax6, Tbr2, and Tbr1 are expressed sequentially by radial glia, intermediate progenitor cells, and postmitotic neurons in developing neocortex. J Neurosci 2005; 25:247-51. [PMID: 15634788]

50. Scardigli R, Bäumer N, Gruss P, Guillemot F, Le Roux I. Direct and concentration-dependent regulation of the proneural gene Neuroginin2 by Pax6. Development 2003; 130:3269-81. [PMID: 12783797]

51. van Heyningen V, Williamson KA. PAX6 in sensory development. Hum Mol Genet 2002; 11:1161-7. [PMID: 12015275]

52. Spalice A, Parisi P, Nicita F, Pizzardi G, Del Balzo F, Iannetti P. Neuronal migration disorders: clinical, neuroradiologic and genetics aspects. Acta Paediatr 2009; 98:421-33. [PMID: 19120042]

53. Mitchell TN, Free SL, Williamson KA, Stevens JM, Churchill AJ, Hanson IM, Shorvon SD, Moore AT, van Heyningen V, Sisodiya SM. Polymicrogyria and absence of pineal gland due to PAX6 mutation. Ann Neurol 2003; 53:658-63. [PMID: 12731001]